Medicenna Therapeutics (TSE:MDNA) Shares Cross Below 200-Day Moving Average – What’s Next?

Medicenna Therapeutics Corp. (TSE:MDNA) crossed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of C$1.79 and traded as low as C$0.93. Medicenna Therapeutics shares last traded at C$1.03, with a volume of 129,478 shares trading hands.

Medicenna Therapeutics Price Performance

The stock has a 50-day moving average of C$1.34 and a two-hundred day moving average of C$1.79. The firm has a market cap of C$77.06 million, a price-to-earnings ratio of -2.84 and a beta of 1.21. The company has a current ratio of 11.40, a quick ratio of 4.65 and a debt-to-equity ratio of 0.88.

Insiders Place Their Bets

In other Medicenna Therapeutics news, Senior Officer David Hyman purchased 20,000 shares of the stock in a transaction dated Thursday, January 9th. The shares were acquired at an average price of C$1.45 per share, for a total transaction of C$29,000.00. Corporate insiders own 22.57% of the company’s stock.

Medicenna Therapeutics Company Profile

Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment.